Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Farnesyltransferase inhibitors lacking a thiol moiety from Merck & Co.

Dec. 19, 1997

More on protein farnesyltransferase inhibitors from Merck & Co.

Dec. 18, 1997

Chemoprotective properties of lisofylline reported

Dec. 18, 1997

Indomethacin: antitumor activity and effects on telomerase

Dec. 17, 1997

Clinical evaluation of adenoviral-p53 gene therapy for prostate cancer begins

Dec. 17, 1997

Burzynski's antineoplastons in phase II testing for multiple oncology indications

Dec. 17, 1997

Neovascularization inhibitors from Tsumura Juntendo

Dec. 17, 1997

Farnesyltransferase inhibitors claimed by Banyu

Dec. 17, 1997

Aronex presents preliminary phase II results on Atragen

Dec. 16, 1997

Second-generation antisense antitumor compound from Hybridon enters clinic

Dec. 16, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...